Polarization  ||| S:0 E:13 ||| NNP
of  ||| S:13 E:16 ||| IN
human  ||| S:16 E:22 ||| JJ
monocyte-derived  ||| S:22 E:39 ||| JJ
dendritic  ||| S:39 E:49 ||| JJ
cells  ||| S:49 E:55 ||| NNS
to  ||| S:55 E:58 ||| TO
DC1  ||| S:58 E:62 ||| CD
by  ||| S:62 E:65 ||| IN
in  ||| S:65 E:68 ||| IN
vitro  ||| S:68 E:74 ||| JJ
stimulation  ||| S:74 E:86 ||| NN
with  ||| S:86 E:91 ||| IN
Newcastle  ||| S:91 E:101 ||| NNP
Disease  ||| S:101 E:109 ||| NNP
Virus  ||| S:109 E:115 ||| NNP
Dendritic  ||| S:115 E:125 ||| NNP
cell  ||| S:125 E:130 ||| NN
( ||| S:130 E:131 ||| -LRB-
DC ||| S:131 E:133 ||| NNP
) ||| S:133 E:134 ||| -RRB-
-based  ||| S:134 E:141 ||| JJ
tumor  ||| S:141 E:147 ||| NN
vaccines  ||| S:147 E:156 ||| NNS
have  ||| S:156 E:161 ||| VBP
been  ||| S:161 E:166 ||| VBN
tested  ||| S:166 E:173 ||| VBN
extensively  ||| S:173 E:185 ||| RB
to  ||| S:185 E:188 ||| TO
treat  ||| S:188 E:194 ||| VB
cancer  ||| S:194 E:201 ||| NN
patients ||| S:201 E:209 ||| NNS
.  ||| S:209 E:211 ||| .
However ||| S:211 E:218 ||| RB
,  ||| S:218 E:220 ||| ,
the  ||| S:220 E:224 ||| DT
results  ||| S:224 E:232 ||| NNS
of  ||| S:232 E:235 ||| IN
several  ||| S:235 E:243 ||| JJ
DC-based  ||| S:243 E:252 ||| JJ
clinical  ||| S:252 E:261 ||| JJ
trials  ||| S:261 E:268 ||| NNS
have  ||| S:268 E:273 ||| VBP
been  ||| S:273 E:278 ||| VBN
disappointing ||| S:278 E:291 ||| JJ
.  ||| S:291 E:293 ||| .
Amelioration  ||| S:293 E:306 ||| NNP
of  ||| S:306 E:309 ||| IN
such  ||| S:309 E:314 ||| PDT
a  ||| S:314 E:316 ||| DT
modality  ||| S:316 E:325 ||| NN
for  ||| S:325 E:329 ||| IN
cancer  ||| S:329 E:336 ||| NN
treatment  ||| S:336 E:346 ||| NN
seems  ||| S:346 E:352 ||| VBZ
warranted ||| S:352 E:361 ||| VBN
,  ||| S:361 E:363 ||| ,
i.e.  ||| S:363 E:368 ||| FW
by  ||| S:368 E:371 ||| IN
improving  ||| S:371 E:381 ||| VBG
DC  ||| S:381 E:384 ||| NNP
immunogenicity  ||| S:384 E:399 ||| NN
and  ||| S:399 E:403 ||| CC
polarization ||| S:403 E:415 ||| NN
.  ||| S:415 E:417 ||| .
The  ||| S:417 E:421 ||| DT
goal  ||| S:421 E:426 ||| NN
of  ||| S:426 E:429 ||| IN
our  ||| S:429 E:433 ||| PRP$
study  ||| S:433 E:439 ||| NN
was  ||| S:439 E:443 ||| VBD
to  ||| S:443 E:446 ||| TO
evaluate  ||| S:446 E:455 ||| VB
the  ||| S:455 E:459 ||| DT
potential  ||| S:459 E:469 ||| NN
for  ||| S:469 E:473 ||| IN
immune  ||| S:473 E:480 ||| JJ
activation  ||| S:480 E:491 ||| NN
of  ||| S:491 E:494 ||| IN
human  ||| S:494 E:500 ||| JJ
DCs  ||| S:500 E:504 ||| NN
by  ||| S:504 E:507 ||| IN
incubating  ||| S:507 E:518 ||| VBG
them  ||| S:518 E:523 ||| PRP
in  ||| S:523 E:526 ||| IN
vitro  ||| S:526 E:532 ||| NN
with  ||| S:532 E:537 ||| IN
the  ||| S:537 E:541 ||| DT
Newcastle  ||| S:541 E:551 ||| NNP
Disease  ||| S:551 E:559 ||| NNP
Virus  ||| S:559 E:565 ||| NNP
( ||| S:565 E:566 ||| -LRB-
NDV ||| S:566 E:569 ||| NNP
) ||| S:569 E:570 ||| -RRB-
,  ||| S:570 E:572 ||| ,
a  ||| S:572 E:574 ||| DT
paramyxovirus  ||| S:574 E:588 ||| NN
with  ||| S:588 E:593 ||| IN
strong  ||| S:593 E:600 ||| JJ
immunostimulatory  ||| S:600 E:618 ||| JJ
properties ||| S:618 E:628 ||| NNS
.  ||| S:628 E:630 ||| .
In  ||| S:630 E:633 ||| IN
vitro  ||| S:633 E:639 ||| JJ
infection  ||| S:639 E:649 ||| NN
with  ||| S:649 E:654 ||| IN
NDV  ||| S:654 E:658 ||| NNP
of  ||| S:658 E:661 ||| IN
human  ||| S:661 E:667 ||| JJ
monocyte-derived  ||| S:667 E:684 ||| JJ
DCs--generated  ||| S:684 E:699 ||| NN
from  ||| S:699 E:704 ||| IN
peripheral  ||| S:704 E:715 ||| JJ
monocytes  ||| S:715 E:725 ||| JJ
cultured  ||| S:725 E:734 ||| NN
with  ||| S:734 E:739 ||| IN
IL-4  ||| S:739 E:744 ||| NN
and  ||| S:744 E:748 ||| CC
GM-CSF--induces  ||| S:748 E:764 ||| JJ
the  ||| S:764 E:768 ||| DT
generation  ||| S:768 E:779 ||| NN
of  ||| S:779 E:782 ||| IN
viral  ||| S:782 E:788 ||| JJ
M  ||| S:788 E:790 ||| NNP
gene  ||| S:790 E:795 ||| NN
transcripts  ||| S:795 E:807 ||| NNS
and  ||| S:807 E:811 ||| CC
RIG-I  ||| S:811 E:817 ||| JJ
expression  ||| S:817 E:828 ||| NN
within  ||| S:828 E:835 ||| IN
DCs ||| S:835 E:838 ||| JJ
.  ||| S:838 E:840 ||| .
Expression  ||| S:840 E:851 ||| NN
of  ||| S:851 E:854 ||| IN
both  ||| S:854 E:859 ||| DT
genes  ||| S:859 E:865 ||| NNS
was  ||| S:865 E:869 ||| VBD
increased  ||| S:869 E:879 ||| VBN
upon  ||| S:879 E:884 ||| IN
co-stimulation  ||| S:884 E:899 ||| JJ
with  ||| S:899 E:904 ||| IN
LPS ||| S:904 E:907 ||| NNP
.  ||| S:907 E:909 ||| .
Surprisingly ||| S:909 E:921 ||| RB
,  ||| S:921 E:923 ||| ,
LPS  ||| S:923 E:927 ||| NNP
and  ||| S:927 E:931 ||| CC
NDV  ||| S:931 E:935 ||| NNP
had  ||| S:935 E:939 ||| VBD
opposite  ||| S:939 E:948 ||| JJ
effects  ||| S:948 E:956 ||| NNS
on  ||| S:956 E:959 ||| IN
induction  ||| S:959 E:969 ||| NN
of  ||| S:969 E:972 ||| IN
interferon  ||| S:972 E:983 ||| NNS
( ||| S:983 E:984 ||| -LRB-
IFN ||| S:984 E:987 ||| NNP
) ||| S:987 E:988 ||| -RRB-
-alpha ||| S:988 E:994 ||| JJ
.  ||| S:994 E:996 ||| .
Furthermore ||| S:996 E:1007 ||| RB
,  ||| S:1007 E:1009 ||| ,
NDV  ||| S:1009 E:1013 ||| FW
induced  ||| S:1013 E:1021 ||| FW
DC  ||| S:1021 E:1024 ||| FW
maturation  ||| S:1024 E:1035 ||| FW
( ||| S:1035 E:1036 ||| -LRB-
as  ||| S:1036 E:1039 ||| RB
measured  ||| S:1039 E:1048 ||| VBN
by  ||| S:1048 E:1051 ||| IN
TNF-alpha  ||| S:1051 E:1061 ||| JJ
production  ||| S:1061 E:1072 ||| NN
and  ||| S:1072 E:1076 ||| CC
CD80  ||| S:1076 E:1081 ||| CD
cell  ||| S:1081 E:1086 ||| NN
surface  ||| S:1086 E:1094 ||| NN
expression ||| S:1094 E:1104 ||| NN
)  ||| S:1104 E:1106 ||| -RRB-
only  ||| S:1106 E:1111 ||| RB
in  ||| S:1111 E:1114 ||| IN
the  ||| S:1114 E:1118 ||| DT
presence  ||| S:1118 E:1127 ||| NN
of  ||| S:1127 E:1130 ||| IN
LPS ||| S:1130 E:1133 ||| NNP
.  ||| S:1133 E:1135 ||| .
Most  ||| S:1135 E:1140 ||| RBS
interestingly ||| S:1140 E:1153 ||| RB
,  ||| S:1153 E:1155 ||| ,
an  ||| S:1155 E:1158 ||| DT
optimal  ||| S:1158 E:1166 ||| JJ
combination  ||| S:1166 E:1178 ||| NN
of  ||| S:1178 E:1181 ||| IN
NDV  ||| S:1181 E:1185 ||| NNP
and  ||| S:1185 E:1189 ||| CC
LPS  ||| S:1189 E:1193 ||| NNP
caused  ||| S:1193 E:1200 ||| VBD
polarization  ||| S:1200 E:1213 ||| VBN
of  ||| S:1213 E:1216 ||| IN
the  ||| S:1216 E:1220 ||| DT
DCs  ||| S:1220 E:1224 ||| JJ
to  ||| S:1224 E:1227 ||| TO
Th1  ||| S:1227 E:1231 ||| CD
type  ||| S:1231 E:1236 ||| NN
cytokines  ||| S:1236 E:1246 ||| NN
with  ||| S:1246 E:1251 ||| IN
a  ||| S:1251 E:1253 ||| DT
high  ||| S:1253 E:1258 ||| JJ
ratio  ||| S:1258 E:1264 ||| NN
of  ||| S:1264 E:1267 ||| IN
interleukin  ||| S:1267 E:1279 ||| NNS
( ||| S:1279 E:1280 ||| -LRB-
IL ||| S:1280 E:1282 ||| NNP
) ||| S:1282 E:1283 ||| -RRB-
-12  ||| S:1283 E:1287 ||| CD
to  ||| S:1287 E:1290 ||| TO
IL-10 ||| S:1290 E:1295 ||| CD
.  ||| S:1295 E:1297 ||| .
These  ||| S:1297 E:1303 ||| DT
in  ||| S:1303 E:1306 ||| IN
vitro  ||| S:1306 E:1312 ||| JJ
results  ||| S:1312 E:1320 ||| NNS
provide  ||| S:1320 E:1328 ||| VBP
a  ||| S:1328 E:1330 ||| DT
means  ||| S:1330 E:1336 ||| NNS
and  ||| S:1336 E:1340 ||| CC
protocol  ||| S:1340 E:1349 ||| NN
for  ||| S:1349 E:1353 ||| IN
maturation  ||| S:1353 E:1364 ||| NN
and  ||| S:1364 E:1368 ||| CC
activation  ||| S:1368 E:1379 ||| NN
of  ||| S:1379 E:1382 ||| IN
DCs  ||| S:1382 E:1386 ||| JJ
with  ||| S:1386 E:1391 ||| IN
enhanced  ||| S:1391 E:1400 ||| JJ
and  ||| S:1400 E:1404 ||| CC
sustained  ||| S:1404 E:1414 ||| JJ
T  ||| S:1414 E:1416 ||| NN
helper  ||| S:1416 E:1423 ||| NN
type  ||| S:1423 E:1428 ||| NN
1-polarizing  ||| S:1428 E:1441 ||| CD
capacity ||| S:1441 E:1449 ||| NN
.  ||| S:1449 E:1451 ||| .
Such  ||| S:1451 E:1456 ||| JJ
pretreated  ||| S:1456 E:1467 ||| JJ
DCs  ||| S:1467 E:1471 ||| NN
may  ||| S:1471 E:1475 ||| MD
significantly  ||| S:1475 E:1489 ||| RB
improve  ||| S:1489 E:1497 ||| VB
DC-based  ||| S:1497 E:1506 ||| JJ
cancer  ||| S:1506 E:1513 ||| NN
immunotherapy ||| S:1513 E:1526 ||| NN
.  ||| S:1526 E:1528 ||| .
The  ||| S:1528 E:1532 ||| DT
data  ||| S:1532 E:1537 ||| NNS
encourage  ||| S:1537 E:1547 ||| VBP
the  ||| S:1547 E:1551 ||| DT
use  ||| S:1551 E:1555 ||| NN
of  ||| S:1555 E:1558 ||| IN
RNA-based  ||| S:1558 E:1568 ||| JJ
viral  ||| S:1568 E:1574 ||| JJ
vectors  ||| S:1574 E:1582 ||| NN
as  ||| S:1582 E:1585 ||| IN
potential  ||| S:1585 E:1595 ||| JJ
novel  ||| S:1595 E:1601 ||| NN
and  ||| S:1601 E:1605 ||| CC
powerful  ||| S:1605 E:1614 ||| JJ
gene  ||| S:1614 E:1619 ||| NN
transfer  ||| S:1619 E:1628 ||| NN
modality  ||| S:1628 E:1637 ||| NN
for  ||| S:1637 E:1641 ||| IN
cytoplasmic  ||| S:1641 E:1653 ||| JJ
gene  ||| S:1653 E:1658 ||| NN
expression  ||| S:1658 E:1669 ||| NN
in  ||| S:1669 E:1672 ||| IN
professional  ||| S:1672 E:1685 ||| JJ
antigen-presenting  ||| S:1685 E:1704 ||| JJ
cells  ||| S:1704 E:1710 ||| NNS
( ||| S:1710 E:1711 ||| -LRB-
APC ||| S:1711 E:1714 ||| NNP
)  ||| S:1714 E:1716 ||| -RRB-
to  ||| S:1716 E:1719 ||| TO
overcome  ||| S:1719 E:1728 ||| VB
immunosuppression  ||| S:1728 E:1746 ||| VBN
in  ||| S:1746 E:1749 ||| IN
cancer  ||| S:1749 E:1756 ||| NN
patients ||| S:1756 E:1764 ||| NNS
.  ||| S:1764 E:1766 ||| .
